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Introduction 
Checkpoint inhibitor immunotherapy is used in the 
treatment of numerous malignancies, including in 
trials for ovarian cancer, and is associated with 
immune-related adverse events (irAEs), [1]. Different 
immunotherapy classes, such as cytotoxic T 
lymphocyte-associated antigen 4 and programmed 
cell death 1 receptor inhibitors, vary in rates of irAEs 
and affect nearly every organ system [1, 2]. Risk of 
irAEs is higher when immunotherapies are used in 
combination [1]. Dermatologic reactions are the 
most common and often earliest to appear [3]. We 
report a case of drug-induced subacute cutaneous 
lupus erythematosus (SCLE) in the setting of 
combination immunotherapy with ipilimumab and 
nivolumab.  
 
Case Synopsis 
A 75-year-old woman was diagnosed with 
metastatic, high grade, serous ovarian carcinoma in 
2011. The patient underwent numerous treatments, 
including combination docetaxel, carboplatin, 
bevacizumab; gemcitabine; pegylated liposomal 
doxorubicin (discontinued due to hand foot 
syndrome); etoposide; topotecan; tamoxifen; 
pemetrexed; anastrozole; and niraparib. Owing to 
progression of disease, combination ipilimumab and 
nivolumab was initiated in May 2018. She developed 
fatigue and a few days after receiving cycle two, she 
developed a pruritic eruption on her arms, thighs, 
and abdomen. Treatments that yielded only mild 
improvement in her symptoms included 
hydroxyzine, triamcinolone 0.1% cream, and 
gabapentin 200mg three times daily. A prednisone 
taper starting at 40mg daily improved her pruritus 
and leg lesions. After receiving the next cycle of 
immunotherapy, her eruption flared, prompting her 
oncology team to hold immunotherapy, increase the 
Abstract 
Checkpoint inhibitor immunotherapy, including 
ipilimumab and nivolumab, is associated with 
numerous immune-related adverse events including 
dermatitis, pruritus, hepatitis, diarrhea, and 
hypophysitis. As the number of patients undergoing 
immunotherapy treatment increases, however, rare 
and unusual immune-related adverse events are 
observed. Many of these resemble known 
autoimmune phenomenon, such as subacute lupus 
erythematosus and myositis. Herein, we report a 
patient with metastatic serous ovarian carcinoma 
undergoing treatment with combination ipilimumab 
and nivolumab who developed subacute cutaneous 
lupus erythematosus (SCLE). Recent case reports 
have documented SCLE as a novel immune-related 
adverse event. In our case, she was able to 
successfully restart immunotherapy after a course of 
oral corticosteroids and maintenance oral 
hydroxychloroquine and topical corticosteroid 
therapy. 
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prednisone dose, and request a dermatology 
consultation. 
Examination demonstrated bilateral cheek erythema 
and erythematous, red-brown, scaly plaques with an 
arcuate appearance widespread on the back, 
abdomen, arms, and legs (Figure 1). Punch biopsy of 
the thigh showed interface lymphocytic infiltrate 
with focal basal vacuolar change (Figure 2). Serum 
studies revealed an elevated anti-nuclear antibody 
(ANA) at 1:160 with speckled pattern, and elevated 
Sjögren syndrome-A (SS-A or Ro) antibody at >8.0 AI 
(normal 0-0.9 AI). Remaining autoimmune panel, 
including SS-B/La, anti-dsDNA, and anti-Smith 
antibodies was negative. Other concurrent 
medications were albuterol, ascorbic acid, cetirizine, 
cholecalciferol, cyclosporine, desipramine, 
eletriptan, gabapentin, hydroxyzine, levetiracetam, 
levothyroxine, metoclopramide, metoprolol, 
niraparib, ondansetron, prochlorperazine, and 
prednisone 10 mg daily. She denied a history of 
autoimmune disease, xerostomia, and 
xerophthalmia. A diagnosis of drug-induced SCLE 
secondary to immunotherapy was made. 
The prednisone dose was increased back to 40mg 
daily and hydroxychloroquine 200mg twice daily 
was initiated. Within one week the eruption largely 
resolved into hyperpigmented patches. Two weeks 
later she restarted immunotherapy with nivolumab 
and ipilimumab and experienced recurrence of a 
mild facial eruption, which quickly resolved with 
triamcinolone 0.1% cream. Prednisone was 
discontinued after six weeks. The patient’s treatment 
course was then switched to pembrolizumab 
monotherapy, which triggered a slight flare in her 
SCLE eruption on her chest and back. 
Hydroxychloroquine, along with all her other 
medications was continued, while quinacrine 100mg 
daily was added, which led to improvement of her 
rash. She has not had a significant flare of the 
eruption with subsequent pembrolizumab cycles. 
 
Case Discussion 
Subacute cutaneous lupus erythematosus is an 
autoimmune disease that can occur spontaneously, 
in conjunction with systemic lupus erythematosus or 
Sjögren syndrome, or as a reaction to medication [4]. 
It presents with a characteristic cutaneous eruption 
often in photoexposed areas and is frequently 
associated with predisposing HLA haplotypes or SS- 
  
 
Figure 1. Clinical Appearance. Numerous scattered 
erythematous papules and plaques with scale, many with an 
annular configuration, over the bilateral lower extremities. 
Similar papules and plaques were found on the back, abdomen, 
and upper and lower arms. 
 
 
Figure 2. Histopathologic Appearance. Hematoxylin and eosin 
stained skin biopsy demonstrated a lymphocytic interface and 
perivascular dermatitis with basal vacuolar change and 
hyperkeratosis. 200×, scale bar=100m. 
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A/Ro antibodies [4]. Drug-induced SCLE (DI-SCLE) is 
most frequently reported in association with thiazide 
diuretics, calcium channel blockers, and antifungals, 
as well as numerous other drugs. In recent years, 
there have also been rising reports of DI-SCLE 
occurring secondary to proton pump inhibitors [5]. 
The most effective treatment for DI-SCLE is 
discontinuation of the offending drug [4]. Besides 
nivolumab, none of the patient’s medications were 
new to her and have not been reported to cause DI-
SCLE [4]. SCLE has recently been reported to occur 
during anti-PD-1 and anti-PD-L1 immunotherapy [6-
8]. In these cases, most resolved with topical 
corticosteroids whereas two required 
hydroxychloroquine and one a short course of oral 
corticosteroids. 
It is unclear whether immunotherapy-induced SCLE 
represents cutaneous toxicity or unmasking of 
subclinical disease, like immunotherapy-induced 
psoriasiform eruptions or dermatomyositis [3]. 
Histopathologic differences between DI-SCLE and 
classic SCLE have been reported to include increased 
dermal mucin deposition with IgM and C3c on direct 
immunofluorescence in classic SCLE [9]. Although DI-
SCLE was reported to have an increased presence of 
leukocytoclastic vasculitis, it was present in only 
about 10% of DI-SCLE samples and was also absent 
in our patient [9]. Results of testing for ANA, anti-
Ro/La, anti-ds DNA, and histones could not 
distinguish between patients with DI-SCLE or 
idiopathic SCLE [9]. As in many other autoimmune 
phenomenon, the presence of autoantibodies 
suggests a B cell response to immunotherapy [3]. 
 
Conclusion 
The appearance of a dermatologic toxicity to 
checkpoint inhibitor immunotherapy warrants 
prompt referral to an appropriate specialist for 
management. Early identification and treatment of 
immunotherapy-induced SCLE can possibly prevent 
treatment interruption or discontinuation of life-
saving immunotherapy. Immunotherapy-induced 
SCLE can be managed with a combination of topical 
corticosteroids, hydroxychloroquine and/or 
quinacrine, and a short course of oral corticosteroids 
to obtain rapid disease control. 
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